Your Partner. For science. For life.
Battling chronic ailments. Evolving science. Improving quality of life. Even helping people get a better night’s sleep. Our portfolio companies are positively impacting the world every day with their visionary people and life-changing products.
What they do.
Enzymatics is a leading producer of sample preparation reagents, diagnostic assays, kits, and software for life science research and applied science customers worldwide. The company develops and manufacture enzymes, buffers, formulations and has a complete product portfolio that complements high value industrial PCR, NGS, SynBio markets.
PBM Capital partners founded Enzymatics and were on the Board until 2015 when it sold the business to Qiagen (NASDAQ:QGEN).
Achievement of Note:
Enzymatics is widely recognized as designing and producing the world’s best molecular biology enzymes. Their enzymes are used in over 75% of all sequencing reactions globally.
How they‘re improving the quality of peoples lives:
Enzymatics has been an enabling factor in rapid decline in cost of next-gen sequencing. This reduction in cost is a catalyst for a new segment of nucleic acid-based diagnostics that will revolutionize personalized healthcare.